Latest Archives - PBD Biotech

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023

PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023

Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023

Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022

Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive step towards achieving the United Nations political declaration to eliminate TB by 2030.

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022

Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive...

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022

Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...

Improved diagnostics priority in Global Plan to End TB

November 21, 2022

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.

Improved diagnostics priority in Global Plan to End TB

November 21, 2022

The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in...

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022

For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs) to assist developers of new diagnostics.

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022

For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs)...

Who is most at risk of developing TB?

November 14, 2022

Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected person coughs or sneezes. Many people carry the disease without realising, creating a reservoir of disease in a population.

Who is most at risk of developing TB?

November 14, 2022

Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected...

Rapid screening of high risk populations for latent TB

November 14, 2022

Estimates suggest that a third of the people in the world have latent TB - this is more than 13 million people in the US. Not all are at risk of the disease, so diagnostics are needed for targeting treatment.

Rapid screening of high risk populations for latent TB

November 14, 2022

Estimates suggest that a third of the people in the world have latent TB - this is more than 13...

Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022

Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022

Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...

Rapid Research in Diagnostics Development for TB Network R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage tuberculosis - is partnering with the Rapid Research in Diagnostics...

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech,...

5 October 2022

See us at The Dairy Show

September 6, 2022

Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to talk about our new blood test and bulk milk test with producers, cheesemakers, dairy companies and others across the industry...

Phage Based Diagnostics

Latest

Targeting global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

Words Matter – how a shared language will accelerate development of TB diagnostics

Words Matter – how a shared language will accelerate development of TB diagnostics

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

Improved diagnostics priority in Global Plan to End TB

Improved diagnostics priority in Global Plan to End TB

WHO Target Product Profile (TPP) for Tuberculosis

WHO Target Product Profile (TPP) for Tuberculosis

Who is most at risk of developing TB?

Who is most at risk of developing TB?

Rapid screening of high risk populations for latent TB

Rapid screening of high risk populations for latent TB

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

5 October 2022

See us at The Dairy Show

5 October 2022

See us at The Dairy Show

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

Mondana Cook joins PBD Biotech to bring human TB diagnostic to market

developers of phage-based diagnostics